Because they are very early in their trial(s) but still wanted to get something out at ASCO, that's why.
Just from the press release, I would say that the clvs drug is different, but not better. The drug is noted as an irreversible inhibitor - very interesting - and with no maximum tolerated dose found yet. But the anemia AE is notable - no explanation, but that is not an AE to dismiss.
Still, it is competition.
News 
Market Data 
Discover 
